Heparin Sensitivity and Resistance
Authors:
- Alan FinleyAFAlan Finley
- Charles GreenbergCGCharles Greenberg
- 1 June 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 116 (6) , 1210-1222
Abstract
Heparin resistance during cardiac surgery is defined as the inability of an adequate heparin dose to increase the activated clotting time (ACT) to the desired level. Failure to attain the target ACT raises concerns that the patient is not fully anticoagulated and initiating cardiopulmonary bypass may result in excessive activation of the hemostatic system. Although antithrombin deficiency has generally been thought to be the primary mechanism of heparin resistance, the reasons for heparin resistance are both complex and multifactorial. Furthermore, the ACT is not specific to heparin's anticoagulant effect and is affected by multiple variables that are commonly present during cardiac surgery. Due to these many variables, it remains unclear whether decreased heparin responsiveness as measured by the ACT represents inadequate anticoagulation. Nevertheless, many clinicians choose a target ACT to assess anticoagulation, and interventions aimed at achieving the target ACT are routinely performed in the setting of heparin resistance. Treatments for heparin resistance/alterations in heparin responsiveness include additional heparin or antithrombin supplementation. In this review, we discuss the variability of heparin potency, heparin responsiveness as measured by the ACT, and the current management of heparin resistance.Keywords
This publication has 152 references indexed in Scilit:
- An Unusual Cause of a Prolonged Activated Coagulation Time During Cardiac Surgery: Congenital HypofibrinogenemiaJournal of Cardiothoracic and Vascular Anesthesia, 2008
- Coagulation and Fibrinolysis in Primary Biliary Cirrhosis Compared With Other Liver Disease and During Orthotopic Liver TransplantationHepatology, 1997
- Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)The American Journal of Cardiology, 1995
- Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery diseaseThe American Journal of Cardiology, 1993
- Intravenous nitroglycerin-induced heparin resistance: A qualitative antithrombin III abnormalityAmerican Heart Journal, 1990
- Blood transfusion requirements in coronary artery surgery with and without the activated clotting time (ACT) techniqueJournal of Molecular Medicine, 1985
- Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activityBiochemical and Biophysical Research Communications, 1983
- Antithrombin III in Fresh Frozen Plasma, Cryoprecipitate, and Cryoprecipitate‐depleted PlasmaTransfusion, 1979
- Pharmacokinetic modeling of heparin and its clinical implicationsJournal of Pharmacokinetics and Biopharmaceutics, 1979
- Highly active heparin species with multiple binding sites for antithrombinBiochemical and Biophysical Research Communications, 1979